Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $4 | $6 | $0 | $2 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $0 | $1 | $1 |
| Total Curr. Assets | $5 | $7 | $1 | $3 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $1 | $1 | $1 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $1 | $1 | $1 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $6 | $8 | $2 | $4 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $3 | $2 |
| Short-Term Debt | $1 | $1 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $1 | $1 | $1 |
| Other Curr. Liab. | $4 | $4 | $5 | $6 |
| Total Curr. Liab. | $8 | $8 | $9 | $10 |
| LT Debt | $0 | $0 | $2 | $2 |
| Deferred Rev, NC | $1 | $1 | $1 | $1 |
| Deferred Tax Liab, NC | $0 | -$1 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $1 | $3 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $9 | $9 | $12 | $13 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$386 | -$384 | -$389 | -$388 |
| AOCI | -$3 | -$1 | -$0 | $0 |
| Other Equity | $386 | $383 | $379 | $379 |
| Total Equity | -$3 | -$1 | -$10 | -$8 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $6 | $8 | $2 | $4 |
| Net Debt | -$3 | -$5 | $2 | $0 |